Home › Funds › Patient Square Capital LP › ARQT

Patient Square Capital LP position in ARQT

ARCUTIS BIOTHERAPEUTICS INC · Health Care

Patient Square Capital LP reported holding 370,000 shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$9.7M, representing 1.50% of its reported portfolio and ranking #19 among its reported holdings. Patient Square Capital LP has disclosed ARQT holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

Latest position (Q2 2026)370.00K sh
Reported value held$9.70M
Portfolio Weight1.50%
First reportedQ4 2025
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Patient Square Capital LP's ARQT position evolved

Patient Square Capital LP first disclosed a stake in ARQT in Q4 2025 at 210,000 shares (US$6.1M). The position peaked in Q2 2026 at 370,000 shares, worth US$9.7M. Across 3 filings, Patient Square Capital LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q2 2026) shows 370,000 shares valued at US$9.7M — a reduction of -30,645 shares quarter over quarter.. Notable position changes include a 91% increase in Q1 2026 (shares rose 11% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2025 210.00K $6.10M New
Q1 2026 400.64K $9.44M Add
Q2 2026 370.00K $9.70M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About ARQT and 13F data

ARQT (ARCUTIS BIOTHERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in ARQT — the largest reported positions include MONTANOVA CAPITAL, LLC (US$326.1M), Frazier Life Sciences Management, L.P. (US$258.9M), Rubric Capital Management LP (US$216.9M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding ARQT

All ARQT fund holders →

FAQ

How long has Patient Square Capital LP held ARQT?

Patient Square Capital LP has disclosed ARQT holdings in 3 of the last 3 reported quarters, going back to Q4 2025.

What is Patient Square Capital LP's current position in ARQT?

As of Q2 2026, Patient Square Capital LP holds 370.00K shares of ARQT (ARCUTIS BIOTHERAPEUTICS INC), valued at $9.70M, representing 1.50% of its reported portfolio and ranking #19.

Has Patient Square Capital LP been buying or selling ARQT?

In the latest 13F filing (Q2 2026), Patient Square Capital LP reduced its position in ARQT. The position peaked in Q2 2026 at 370.00K shares.

Which other funds hold ARQT?

Other major institutional holders of ARQT include MONTANOVA CAPITAL, LLC, Frazier Life Sciences Management, L.P., Rubric Capital Management LP, among 45 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.